Oramed Pharmaceuticals (ORMP) Common Equity (2011 - 2026)

Oramed Pharmaceuticals has reported Common Equity for 16 years, with the latest figure at $238.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 70.33% year-over-year to $238.3 million; the trailing twelve-month figure through Mar 2026 stood at $238.3 million (up 70.33% YoY), and the FY2025 full-year result was $199.7 million, up 37.43% from the prior year.
• Common Equity for Q1 2026 stood at $238.3 million, up from $199.7 million in the prior quarter.
• The five-year high for Common Equity was $238.3 million in Q1 2026, with the low at $139.9 million in Q1 2025.
• Historically, Common Equity has averaged $165.2 million across 5 years, with a median of $153.6 million in 2025.
• Annual changes were most pronounced in 2025 — Common Equity decreased 15.58% — and 2026, when it soared 70.33%.
• Oramed Pharmaceuticals' Common Equity stood at $151.2 million in 2022, then increased by 7.76% to $162.9 million in 2023, then retreated by 10.77% to $145.3 million in 2024, then soared by 37.43% to $199.7 million in 2025, then grew by 19.29% to $238.3 million in 2026.
• The last three Common Equity figures came in at $238.3 million (Q1 2026), $199.7 million (Q4 2025), and $202.3 million (Q3 2025), per Business Quant data.